CELLYAN BIOTECHNOLOGY CO-A (HKPD) Fundamental Analysis & Valuation

NASDAQ:HKPD • KYG6365B1041

Current stock price

0.73 USD
+0.03 (+4.29%)
At close:
0.739 USD
+0.01 (+1.23%)
After Hours:

This HKPD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. HKPD Profitability Analysis

1.1 Basic Checks

  • HKPD had positive earnings in the past year.
HKPD Yearly Net Income VS EBIT VS OCF VS FCFHKPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 2025 0 500K 1M 1.5M

1.2 Ratios

  • The Return On Assets of HKPD (1.25%) is comparable to the rest of the industry.
  • HKPD has a Return On Equity (2.33%) which is in line with its industry peers.
  • HKPD's Return On Invested Capital of 4.15% is in line compared to the rest of the industry. HKPD outperforms 56.52% of its industry peers.
  • HKPD had an Average Return On Invested Capital over the past 3 years of 41.78%. This is significantly above the industry average of 9.36%.
  • The 3 year average ROIC (41.78%) for HKPD is well above the current ROIC(4.15%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 1.25%
ROE 2.33%
ROIC 4.15%
ROA(3y)14.77%
ROA(5y)N/A
ROE(3y)67.08%
ROE(5y)N/A
ROIC(3y)41.78%
ROIC(5y)N/A
HKPD Yearly ROA, ROE, ROICHKPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 2025 0 50 100 150

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.44%, HKPD is in line with its industry, outperforming 56.52% of the companies in the same industry.
  • HKPD has a Operating Margin of 1.28%. This is comparable to the rest of the industry: HKPD outperforms 52.17% of its industry peers.
  • HKPD has a Gross Margin of 10.80%. This is comparable to the rest of the industry: HKPD outperforms 43.48% of its industry peers.
Industry RankSector Rank
OM 1.28%
PM (TTM) 0.44%
GM 10.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HKPD Yearly Profit, Operating, Gross MarginsHKPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. HKPD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HKPD is creating value.
  • HKPD has about the same amout of shares outstanding than it did 1 year ago.
  • The debt/assets ratio for HKPD is higher compared to a year ago.
HKPD Yearly Shares OutstandingHKPD Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2025 2M 4M 6M 8M 10M
HKPD Yearly Total Debt VS Total AssetsHKPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • An Altman-Z score of 6.10 indicates that HKPD is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.10, HKPD belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
  • A Debt/Equity ratio of 0.28 indicates that HKPD is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.28, HKPD perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 6.1
ROIC/WACC0.5
WACC8.28%
HKPD Yearly LT Debt VS Equity VS FCFHKPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 2025 0 1M 2M 3M 4M

2.3 Liquidity

  • A Current Ratio of 2.92 indicates that HKPD has no problem at all paying its short term obligations.
  • The Current ratio of HKPD (2.92) is better than 82.61% of its industry peers.
  • HKPD has a Quick Ratio of 2.73. This indicates that HKPD is financially healthy and has no problem in meeting its short term obligations.
  • HKPD's Quick ratio of 2.73 is amongst the best of the industry. HKPD outperforms 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.73
HKPD Yearly Current Assets VS Current LiabilitesHKPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. HKPD Growth Analysis

3.1 Past

  • The earnings per share for HKPD have decreased strongly by -100.00% in the last year.
  • HKPD shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.72%.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)21.72%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HKPD Yearly Revenue VS EstimatesHKPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

1

4. HKPD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 73.00, HKPD can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of HKPD is on the same level as its industry peers.
  • The average S&P500 Price/Earnings ratio is at 27.87. HKPD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 73
Fwd PE N/A
HKPD Price Earnings VS Forward Price EarningsHKPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HKPD indicates a somewhat cheap valuation: HKPD is cheaper than 65.22% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.08
HKPD Per share dataHKPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HKPD Dividend Analysis

5.1 Amount

  • HKPD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HKPD Fundamentals: All Metrics, Ratios and Statistics

CELLYAN BIOTECHNOLOGY CO-A

NASDAQ:HKPD (4/17/2026, 8:18:57 PM)

After market: 0.739 +0.01 (+1.23%)

0.73

+0.03 (+4.29%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryAir Freight & Logistics
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.36%
Inst Owner ChangeN/A
Ins Owners38.07%
Ins Owner ChangeN/A
Market Cap17.16M
Revenue(TTM)27.14M
Net Income(TTM)120.00K
AnalystsN/A
Price TargetN/A
Short Float %0%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 73
Fwd PE N/A
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B 3.34
P/tB 3.4
EV/EBITDA 13.08
EPS(TTM)0.01
EY1.37%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.15
BVpS0.22
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.22184 (-69.61%)
Profitability
Industry RankSector Rank
ROA 1.25%
ROE 2.33%
ROCE 5.26%
ROIC 4.15%
ROICexc 4.28%
ROICexgc 4.34%
OM 1.28%
PM (TTM) 0.44%
GM 10.8%
FCFM N/A
ROA(3y)14.77%
ROA(5y)N/A
ROE(3y)67.08%
ROE(5y)N/A
ROIC(3y)41.78%
ROIC(5y)N/A
ROICexc(3y)93.98%
ROICexc(5y)N/A
ROICexgc(3y)95.07%
ROICexgc(5y)N/A
ROCE(3y)52.95%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover2.82
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 1.03
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.73
Altman-Z 6.1
F-ScoreN/A
WACC8.28%
ROIC/WACC0.5
Cap/Depr(3y)13.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)21.72%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-88.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y187.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y244.56%
OCF growth 3YN/A
OCF growth 5YN/A

CELLYAN BIOTECHNOLOGY CO-A / HKPD Fundamental Analysis FAQ

What is the fundamental rating for HKPD stock?

ChartMill assigns a fundamental rating of 3 / 10 to HKPD.


What is the valuation status of CELLYAN BIOTECHNOLOGY CO-A (HKPD) stock?

ChartMill assigns a valuation rating of 1 / 10 to CELLYAN BIOTECHNOLOGY CO-A (HKPD). This can be considered as Overvalued.


Can you provide the profitability details for CELLYAN BIOTECHNOLOGY CO-A?

CELLYAN BIOTECHNOLOGY CO-A (HKPD) has a profitability rating of 3 / 10.


How financially healthy is CELLYAN BIOTECHNOLOGY CO-A?

The financial health rating of CELLYAN BIOTECHNOLOGY CO-A (HKPD) is 6 / 10.